Abstract
Introduction
Angiogenesis, the formation of new blood vessels by sprouting of pre-existing ones, is a main mechanism of vascularization during embryonic development, growth, formation of the corpus luteum and endometrium, regeneration and wound healing. However, deregulated, abnormal angiogenesis is involved in many pathological processes [1, 2] . The complex sequence of events involved in angiogenesis is related to changes in endothelial cell biosignalling [3] . The relationships of angiogenesis with cancer have special relevance, since angiogenesis has been described as one of the hallmarks of cancer, playing an essential role in tumour growth, invasion, and metastasis [4] . Since tumour blood vessels Angiogenesis Review Series [1, 5] [3, 13, 15, 16] . Another possibility is the fractal analysis of the vascular network in tumour biopsies [17] . However, these approaches are far from an ideal biomarker for clinical practice. Although some authors consider taking biopsies repeatedly to be feasible [18] , most physicians consider this to be very cumbersome for patients. Since tumour angiogenesis produces interstitial hypertension in tumours, the determination of interstitial pressure of tumours can be considered an alternative surrogate biomarker [19] . Easier to determine and less invasive approaches include the measurements of circulating levels of several angiogenic factors, but so far no growth factor has been validated for predicting response to antiangiogenic therapy [12, 13] [26] . Angiogenesis-independent tumour growth can occur along pre-existing blood vessels [27] . Another possibility is the 'co-option' of vessels during early growth of tumours in the absence of angiogenesis [11, 28] . On the other hand, vascular mimicry, the generation of microvascular channels by genetically deregulated and aggressive tumour cells, is an alternative way to provide blood supply to tumours and is independent of angiogenesis [29, 30] [31, 32] . Lymphangiogenesis has also been related to metastasis [33] . Pathological angiogenesis is characterized by structurally and functionally abnormal vessels and lymphatic vessels [1, 2] . These abnormalities result from an imbalance between levels of pro-and antiangiogenic molecules. As a result, the blood flow in tumour vessels is chaotic and the vessels are leaky [19] . This, in turn, compromises the delivery and effectiveness of conventional therapies, as well as molecular targeted therapies [34] .
Finally 
Signs of hope
A second generation of antiangiogenic trials is beginning to show highly significant potential [8, 35] [44] . [19, 45] [45] .
From the results obtained so far in clinical trials, it can be concluded that the future clinical success of angiogenesis inhibitors could be related to their use in combination with chemotherapy or radiotherapy. Combined therapies can exert their effects on both tumour and endothelial cells simultaneously. Since abnormal angiogenic vessels compromise the delivery of drugs targeting tumour cells, the normalization of tumour vasculature with antiangiogenic therapy has emerged as a new paradigm for combination therapy

. Synergic effects can be expected, since judiciously applied antiangiogenic therapy can increase the penetrability of chemotherapeutic agents, as well as the radiosensibility of tumour cells. A detailed analysis of how antiangiogenic compounds reduce vessel density shows that these drugs reduce vascular permeability, destroy immature vessels and increase the recruitment of pericytes to stabilize other vessels. This transient stabilization has been termed the normalization window, defined as a period of time where tumour blood flow and oxygenation increases, thus providing an opportunity to better deliver chemotherapeutic drugs and radiation therapy
As previously mentioned, the heterogeneity of blood vessel growth, the fact that angiogenesis differs among tumour types is a basis for the observed differences in response to antiangiogenic therapy in both animal and clinical trials [11] . Therefore, a multidrug approach might be more successful than monotherapy. The [25] .
The initial suggestion that variation in the levels of circulating endothelial progenitor cells could be a useful surrogate marker to monitor angiogenesis has been confirmed and extended in an outstanding report published in Cancer Cell [44] . This report provides evidence that the levels of circulating endothelial progenitor cells are genetically predetermined and regulated by regulators of angiogenesis, including VEGF, Tie-2 and thrombospondin-1. Moreover, antiangiogenic therapy can be optimized by monitoring the levels of both circulating endothelial cells and circulating endothelial progenitor cells [13, 25] . Therefore, the kinetics of these cells in peripheral blood is suggested to be useful surrogate markers of pathological angiogenesis with potential application for the monitoring of antiangiogenic therapy response.
Future avenues for the vascular therapy of cancer
There are clear signs that during the last year antiangiogenesis research has entered a new age. [51] .
Recently, concerns have been raised on the possibility of resistance to antiangiogenic therapy [13, 21] [55, 56] .
Finally, the potentials of angioprevention should also be analyzed [57] 
